@rhshah.bsky.social
Our study just published in European Urology Open Science, conducted as part of the CALGB (Alliance) trial, explores the role of circulating tumor DNA (ctDNA) as a prognostic biomarker in patients with metastatic urothelial carcinoma undergoing cisplatin-based chemotherapy.
tinyurl.com/CALGB-ctDNA
tinyurl.com/CALGB-ctDNA
Circulating Tumor DNA and Response to Cisplatin-based Chemotherapy in Patients with Metastatic Urothelial Carcinoma Enrolled in CALGB 90601 (Alliance)
Cisplatin-based chemotherapy has been a cornerstone of therapy for advanced/metastatic urothelial cancer (mUC). However, no genomic characteristics ha…
tinyurl.com
April 7, 2025 at 9:54 PM
Our study just published in European Urology Open Science, conducted as part of the CALGB (Alliance) trial, explores the role of circulating tumor DNA (ctDNA) as a prognostic biomarker in patients with metastatic urothelial carcinoma undergoing cisplatin-based chemotherapy.
tinyurl.com/CALGB-ctDNA
tinyurl.com/CALGB-ctDNA